Results 11 to 20 of about 65,035 (206)

Psychomotor activity and body weight gain after exposure to low ribavirin doses in rats: role of treatment duration [PDF]

open access: yesArchives of Biological Sciences, 2019
Clinically-related basic studies on the behavioral effects of ribavirin treatment are still lacking despite its wide use as an antiviral medication. This paper considers the effects of low ribavirin doses (10, 20 and 30 mg/kg/day) on psychomotor activity
Petković Branka   +6 more
doaj   +1 more source

Combined therapy with danazol, pegilated interferon, and ribavirin improves thrombocytopenia and liver injury in rats with fibrosis

open access: yesAnnals of Hepatology, 2007
The aim of this study was to investigate the effects of combinations of pegilated–interferon (PEG–IFN), ribavirin, and danazol on thrombocytopenia and liver injury in rats with fibrosis.
Guillermo Cabrera Álvarez   +7 more
doaj   +1 more source

Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. [PDF]

open access: yesPLoS ONE, 2011
The nucleoside analogue Ribavirin significantly increases patient response to IFN-α treatment of HCV, by directly inhibiting viral replication. Recent studies indicate that Ribavirin also regulates immunity and we propose that Ribavirin enhances specific
Nigel J Stevenson   +5 more
doaj   +1 more source

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C [PDF]

open access: yes, 2000
Background/Aims: Combination therapy with interferon-alpha (IFN-alpha) plus ribavirin is more efficacious than IFN-alpha monotherapy in previously untreated patients with chronic hepatitis C and patients with IFN-alpha relapse.
Berg, Thomas   +8 more
core   +1 more source

A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [PDF]

open access: yes, 2019
Background The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was first described in 2012 and attracted a great international attention due to multiple healthcare associated outbreaks.
Al-Ali, Anfal Y.   +2 more
core   +1 more source

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. [PDF]

open access: yes, 2017
Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality.
Bau, Sherona N   +15 more
core   +1 more source

Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. [PDF]

open access: yesPLoS ONE, 2013
Lethal mutagenesis, or virus extinction produced by enhanced mutation rates, is under investigation as an antiviral strategy that aims at counteracting the adaptive capacity of viral quasispecies, and avoiding selection of antiviral-escape mutants.
Ana M Ortega-Prieto   +8 more
doaj   +1 more source

The Use of Aerosolized Ribavirin in Respiratory Syncytial Virus Lower Respiratory Tract Infections in Adult Immunocompromised Patients: A Systematic Review [PDF]

open access: yes, 2019
Introduction: Respiratory syncytial virus (RSV)–associated lower respiratory tract infection (LRTI) is a concern in immunocompromised patients. Aerosolized ribavirin (RBV AER) is used for treatment of RSV LRTI; however, adverse events and rising drug ...
Avery, Lisa M.   +2 more
core   +2 more sources

Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort [PDF]

open access: yes, 2016
BACKGROUND: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings.
Abbas, Zaigham   +303 more
core   +1 more source

Rituximab-Containing Treatment Regimens May Imply a Long-Term Risk for Difficult-To-Treat Chronic Hepatitis E [PDF]

open access: yes, 2020
Hepatitis E virus (HEV) infection is an emerging disease in industrialized countries which is usually characterized by a self-limited course. However, there is an increased risk of HEV persistence in immunocompromised risk populations, comprising ...
Biedermann, Paula   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy